Scientists hunt for immune clues in glioblastoma patients
NCT ID NCT04657146
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects blood and bone marrow samples from 40 adults with newly diagnosed glioblastoma to track changes in immune cells over time. Researchers aim to understand how the immune system responds to the tumor and standard treatments. The goal is to gather foundational data that could lead to new immunotherapy strategies for this aggressive brain cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide foundational data to develop new immunotherapy approaches for glioblastoma.
- What could go wrong
- This is an observational study that does not test a treatment, so it will not directly benefit participants. The study is currently suspended, and results may not lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?